Adherence to Aromatase Inhibitors: The Role of Partners

Completed

• Conditions: Breast Cancer Survivors

• Registration Number: NCT02753985
• Lead Sponsor: Abramson Cancer Center at Penn Medicine

Brief Summary

This is a qualitative study which explores the role that partners play in breast cancer survivors adherence to aromatase inhibitors and management of their side effects. Both patients and their partners will be interviewed (separately) in order to capture multiple perspectives. The target number of subjects is 64 (32 patients and 32 partners). The primary method of data collection will be face-to-face semi-structured interviews. These interviews will be audio-recorded.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-07
• Primary Completion: 2016-04-22
• Study Completion: 2016-04-22
• Study First Submitted: 2016-04-26
• Study First Submitted QC: 2016-04-26
• Study First Posted: 2016-04-28
• Status Verified: 2019-07
• Last Update Submitted: 2019-07-22
• Last Update Posted: 2019-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• Women and partners of women with stage I-III breast cancer who

  1. have completed primary cancer treatments (surgery, chemotherapy, radiotherapy)
  2. have experienced AI side effects
  3. live with a romantic partner.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of Surveys Completed	2 years

Trial Locations

Locations (1)

Abramson Cancer Center of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States